Seminars in Radiation Oncology
Volume 19, Issue 3 , Pages 179-186 , July 2009

Technological Advances in Radiation Oncology for Central Nervous System Tumors

  • Shin-ei Noda, MD, PhD

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • ,
  • Tim Lautenschlaeger, MD

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • ,
  • Michael R. Siedow, BS

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • ,
  • Disha R. Patel, BA

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • ,
  • Areej El-Jawahri, MD

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • ,
  • Yoshiyuki Suzuki, MD, PhD

      Affiliations

    • Department of Radiation Oncology, Gunma University, Graduate School of Medicine, Gunma, Japan
    • ,
  • Jay S. Loeffler, MD

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • ,
  • Marc R. Bussiere, MSc

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA
    • ,
  • Arnab Chakravarti, MD

      Affiliations

    • Department of Radiation Oncology, The Ohio State University Medical School, Columbus, OH
    • Corresponding Author InformationAddress reprint requests to Arnab Chakravarti, MD, Department of Radiation Oncology, The Ohio State University Medical School, 300W. 10th Ave., Room 0808, Columbus, Ohio 43210

References 

  1. Chan MF, Schupak K, Burman C, et al. Comparison of intensity-modulated radiotherapy with three-dimensional conformal radiation therapy planning for glioblastoma multiforme. Med Dosim. 2003;28:261–265
  2. Hermanto U, Frija EK, Lii MJ, et al. Intensity-modulated radiotherapy (IMRT) and conventional three-dimensional conformal radiotherapy for high-grade gliomas: Does IMRT increase the integral dose to normal brain?. Int J Radiat Oncol Biol Phys. 2007;67:1135–1144
  3. Samuelsson AJK. Intensity modulated radiotherapy treatment planning for dynamic multileaf collimator delivery: Influence of different parameters on dose distributions. Int J Radiat Oncol Biol Phys. 2003;66:19–28
  4. Al-Ghazi M, Kuo J, Ramsinghani N, et al. Irvine, University of California experience with tomotherapy using the Peacock system. Med Dosim. 2001;26:17–27
  5. Voynov G, Kaufman S, Hong T, et al. Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. Am J Clin Oncol. 2002;25:606–611
  6. Narayana A, Yamada J, Berry S, et al. Intensity-modulated radiotherapy in high-grade gliomas: Clinical and dosimetric results. Int J Radiat Oncol Biol Phys. 2006;64:892–897
  7. Sultanem K, Patrocinio H, Lambert C, et al. The use of hypofractionated intensitymodulated irradiation in the treatment of glioblastoma multiforme: Preliminary results of a prospective trial. Int J Radiat Oncol Biol Phys. 2004;58:247–252
  8. Fuller CD, Choi M, Forthuber B, et al. Standard fractionation intensity modulated radiation therapy (IMRT) of primary and recurrent glioblastoma multiforme. Radiol Oncol. 2007;2:26–33
  9. Panet-Raymond V, Souhami L, Roberge D, et al. Accelerated hypofractionated intensity-modulated radiotherapy with Concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: A safety and efficacy analysis. Int J Radiat Oncol Biol Phys. 2008;73:473–478
  10. Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand. 1951;102:316–319
  11. Nedzi LA. The implementation of ablative hypofractionated radiotherapy for stereotactic treatments in the brain and body: Observations on efficacy and toxicity in clinical practice. Semin Radiat Oncol. 2008;18:265–272
  12. Hasegawa T, Kondziolka D, Flickinger JC, et al. Brain metastases treated with radiosurgery alone: An alternative to whole brain radiotherapy?. Neurosurgery. 2003;52:1318–1326
  13. Shehata MK, Young B, Reid B, et al. Stereotatic radiosurgery of 468 brain metastases < or =2 cm: Implications for SRS dose and whole brain radiation therapy. Int J Radiat Oncol Biol Phys. 2004;59:87–93
  14. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. J Am Med Assoc. 2006;295:2483–2491
  15. Sneed PK, Lamborn KR, Forstner JM, et al. Radiosurgery for brain metastases: Is whole brain radiotherapy necessary?. Int J Radiat Oncol Biol Phys. 1999;43:549–558
  16. Alexander E, Moriarty TM, Davis RB, et al. Stereotactic radiosurgery for the definitive, noninvasive treatment of brain metastases. J Natl Cancer Inst. 1995;87:34–40
  17. Joseph J, Adler JR, Cox RS, et al. Linear accelerator-based stereotaxic radiosurgery for brain metastases: The influence of number of lesions on survival. J Clin Oncol. 1996;14:1085–1092
  18. Breneman JC, Warnick RE, Albright RE, et al. Stereotactic radiosurgery for the treatment of brain metastases (Results of a single institution series). Cancer. 1997;79:551–557
  19. Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47:291–298
  20. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665–1672
  21. Kondziolka D, Patel A, Lunsford LD, et al. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45:427–434
  22. Chougule PB, Burton-Williams M, Saris S, et al. Randomized treatment of brain metastasis with gamma knife radiosurgery, whole brain radiotherapy or both. Int J Radiat Oncol Biol Phys. 2000;48(Suppl 1):114
  23. Sanghavi SN, Miranpuri SS, Chappell R, et al. Radiosurgery for patients with brain metastases: A multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. Int J Radiat Oncol Biol Phys. 2001;51:426–434
  24. Wang LG, Guo Y, Zhang X, et al. Brain metastasis: Experience of the Xi-Jing Hospital. Stereotact Funct Neurosurg. 2002;78:70–83
  25. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37:745–751
  26. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. J Am Med Assoc. 1998;280:1485–1489
  27. Patel M, Siddiqui F, Jin JY, et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: Radiographic response and improved survival. J Neuro Oncol. 2008;92:185–191
  28. Schwer AL, Damek DM, Kavanagh BD, et al. A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys. 2008;70:993–1001
  29. Lipani JO, Jackson PS, Soltys SG, et al. Survival following CyberKnife radiosurgery and hypofractionated radiotherapy for newly diagnosed glioblastoma multiforme. Technol Cancer Res Treat. 2008;7:249–255
  30. Schulz-Ertner D, Jakel O, Schlegel W. Radiation therapy with charged particles. Semin Radiat Oncol. 2006;16:249–259
  31. Hall E. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65:1–7
  32. Fitzek MM, Thornton AF, Harsh G, et al. Dose-escalation with proton/photon irradiation for Daumas-Duport lower-grade glioma: Results of an institutional phase I/II trial. Int J Radiat Oncol Biol Phys. 2001;51:131–137
  33. Fitzek MM, Thornton AF, Rabinov JD, et al. Accelerated fractionated proton/photon irradiation to 90 cobalt gray equivalent for glioblastoma multiforme: Results of a phase II prospective trial. J Neurosurg. 1999;91:251–260
  34. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25:953–964
  35. Ando K, Koike S, Ohira C, et al. Accelerated reoxygenation of a murine fibrosarcoma after carbon-ion radiation. Int J Radiat Biol. 1999;75:505–512
  36. Nakano T, Suzuki Y, Ohno T, et al. Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia. Clin Cancer Res. 2006;12:2185–2190
  37. In:  Griffin TW editors. Particle-Beam Radiation Therapy. Philadelphia, PA: J.B. Lippincott; 1992;
  38. Mizoe JE, Tsujii H, Hasegawa A, et al. Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: Combined X-ray radiotherapy, chemotherapy and carbon in radiotherapy. Int J Radiat Oncol Biol Phys. 2007;69:390–396
  39. Yamamoto T, Nakai K, Matsumura A. Boron neutron capture therapy for glioblastoma. Cancer Lett. 2008;262:143–152
  40. Barth RF, Coderre JA, Vicente MG, et al. Boron neutron capture therapy of cancer: Current status and future prospects. Clin Cancer Res. 2005;11:3987–4002
  41. Chanana AD, Capala J, Chadha M, et al. Boron neutron capture therapy for glioblastoma multiforme: Interim results from the phase I/II dose-escalation studies. Neurosurgery. 1999;44:1182–1192
  42. Busse PM, Harling OK, Palmer MR, et al. A critical examination of the results from the Harvard-mit NCT program phase I clinical trial of neutron capture therapy for intracranial disease. J Neuro Oncol. 2003;62:111–121
  43. Diaz AZ. Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician's point of view. J Neuro Oncol. 2003;62:101–109
  44. Yamamoto T, Matsumura A, Nakai K, et al. Current clinical results of the Tsukuba BNCT trial. Appl Radiol Isot. 2004;61:1089–1093
  45. Wittig A, Hideghéty K, Paquis P, et al. Current clinical results of the EORTC-study. In:  Surewein W,  Wittig A editor. Research and Development in Neutron Capture Therapy. Bologna: Monduzzi Editore; 2002;p. 11961;RM
  46. Capala J, Stenstam BH, Skold K, et al. Boron neutron capture therapy for glioblastoma multiforme: clinical studies in Sweden. J Neurooncol. 2003;62:135–144
  47. Coderre JA, Hopewell JW, Turcottea JC, et al. Tolerance of normal human brain to boron neutron capture therapy. Appl Rad Isot. 2004;61:1083–1087
  48. Carlsson J, Kulberg EB, Capala J, et al. Ligand liposomes and boron neutron capture therapy. J Neurooncol. 2003;62:47–59
  49. Ceberg CP, Brun A, Kahl SB, et al. A comparative study on the pharmacokinetics and biodistribution of boronated porphyrin (BOPP) and sulfhydryl boron hydride (BSH) in the RG2 rat glioma model. J Neurosurg. 1995;83:86–92
  50. Kabalka GW, Yao ML. Synthesis of a potential boron neutron capture therapy agent: 1-aminocyclobutane-1-carboxylic acid bearing a butylboronic acid side chain. Synthesis. 2003;18:2890–2893
  51. Diaz A, Laramore G, Wiersema R, et al. Pharmachology studies of Na2B10H10 (GB-10) in human tumor patients. In:  Surewein W,  Wittig A editor. Research and Development in Neutron Capture Therapy. Bologna: Monduzzi Editore; 2002;p. 993–999
  52. Tietze LF, Griesbach U, Bothe U, et al. Novel carboranes with a DNA binding unit for the treatment of cancer by boron neutron capture therapy. Chembiochem. 2002;3:219–225
  53. Tietze LF, Griesbach U, Schuberth I, et al. Novel carboranyl C-glycosides for the treatment of cancer by boron neutron capture therapy. Chem Eur J. 2003;9:1296–1302
  54. El-Zaria ME, Dörfler U, Gabel D. Synthesis of (aminoalkylamine)-N-aminoalkyl)azanonaborane(11) derivatives for boron neutron capture therapy. J Med Chem. 2002;45:5817–5819
  55. Tjarks W. The use of Boron clusters in the rational design of boronated nucleosides for neutron capture therapy of cancer. J Organomet Chem. 2001;614-615:37–47
  56. Al-Madhoun AS, Johnsamuel J, Yan J, et al. Synthesis of a small library of 3-(carboranylalkyl) thymidinesan d their biological evaluation as substrates for human thymidine kinases 1 and 2. J Med Chem. 2002;45:4018–4028
  57. Woodhouse SL. Synthesis and DNA binding properties of dinuclear platinum(II)-amine complexes of 1,7-dicarba-closo-dodecaborane(12). Chem Commun. 2001;7:2464–2465
  58. Olejiniczak AB, Koziolkiewicz M, Lesnikowski ZJ. Carboranyl oligonucleotides. 4. Synth And Physicochem Stud of Oligonucleotides Containing:20-O(o-carboran-1- yl)methyl group. Antisense Nucleic Acid Drug Dev. 2002;12:79–94
  59. Ivanov D, Bachovchin WW, Redfield AG. Boron-11 pure quadrupole resonance investigation of peptide boronic acid inhibitors bound to a-lyticprotease. Biochemistry. 2002;41:1587–1590
  60. Gutin PH, Phillips TL, Wara WM, et al. Brachytherapy of recurrent malignant brain tumors with removable high-activity iodine-125 sources. J Neurosurg. 1984;60:61–68
  61. Selker RG, Shapiro WR, Burger P, et al. The Brain Tumor Cooperative Group NIH trial 87-01: A randomized comparison of surgery, external radiotherapy, and carmustine versus surgery, interstitial radiotherapy boost, external radiation therapy, and carmustine. Neurosurgery. 2002;51:343–357
  62. Gutin PH, Leibel SA, Wara WM, et al. Recurrent malignant gliomas: Survival following interstitial brachytherapy with high activity iodine-125 sources. J Neurosurg. 1987;67:864–873
  63. Bernstein M, Laperrier N, Glen J, et al. Brachytherapy for recurrent malignant astrocytoma. Int J Radiat Oncol Biol Phys. 1994;30:1213–1217
  64. Gutin PH, Hosobuchi Y, Phillips TL, et al. Stereotactic interstitial irradiation for the treatment of tumors. Cancer Treat Rep. 1981;65:103–106
  65. Hosobuchi Y, Phillips TL, Stupar TA, et al. Interstitial brachytherapy of primary brain tumors: Preliminary report. J Neurosurg. 1980;53:613–617
  66. Hitchon PW, VanGlider JC, Wen BC, et al. Brachytherapy for malignant recurrent and untreated gliomas. Stereotact Funct Neurosurg. 1992;59:174–178
  67. Gutin PH, Prados MD, Phillips TL, et al. External irradiation followed by an interstitial high activity iodine-125 implant “boost” in the initial treatment of malignant gliomas: NCOG study 6G-82-2. Int J Radiat Oncol Biol Phys. 1991;21:601–606
  68. Laperriere NJ, Leung PM, McKenzie S, et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys. 1998;41:1005–1011
  69. Loeffler JS, Alexander E, Hochberg FH, et al. Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys. 1990;19:1455–1462
  70. Levin VA, Wara WM, Gutin PH, et al. Initial Anal of NCOG:6G, 82-81: Bromodeoxyuridine (BUdR) during irradiation followed by CCNU, procarbazine, and vincristine (PCV) chemotherapy for malignant glioma. Proc Am Soc Clin Oncol. 1990;9:91
  71. Deutsch M, Green SB, Strike TA, et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the post-operative treatment of malignant gliomas (BTSG 77-02). Int J Radiat Oncol Biol Phys. 1989;16:1389–1396
  72. Frankel R, Stubbs J, Dillehay D, et al. Pre-clinical evaluation of a novel device for delivering brachytherapy to resected brain tumor cavity margins. Int J Radiat Oncol Biol Phys. 1999;45(Suppl 1):319–320
  73. Dempsey JF, Williams JA, Stubbs JB, et al. Dosimetric properties of a novel brachytherapy balloon applicator for the treatment of malignant brain tumor resection-cavity margins. Int J Radiat Oncol Biol Phys. 1998;42:421–429
  74. Monroe JI, Dempsey JF, Dorton JA, et al. Experimental validation of dose calculation algorithms for the GliaSite RTS, a novel 125I liquid-filled balloon brachytherapy applicator. Med Phys. 2001;28:73–85
  75. Tatter SB, Shaw EG, Rosenblum ML, et al. An inflatable balloon catheter and liquid 125I radiation source (GliaSite radiation therapy system) for treatment of recurrent malignant glioma: Multicenter safety and feasibility trial. J Neurosurg. 2003;99:297–303

PII: S1053-4296(09)00023-X

doi: 10.1016/j.semradonc.2009.02.006

Seminars in Radiation Oncology
Volume 19, Issue 3 , Pages 179-186 , July 2009

Article Tools

* Image Usage & Resolution